Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature.

IF 1.3 Q4 RHEUMATOLOGY European journal of rheumatology Pub Date : 2022-04-01 DOI:10.5152/eurjrheum.2022.21059
Brigitte Kazzi, Brent Gudenkauf, Derek Fine, Jose Manuel Monroy-Trujillo, Antoine Azar, Gabriel Giannini, Homa Timlin
{"title":"Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature.","authors":"Brigitte Kazzi,&nbsp;Brent Gudenkauf,&nbsp;Derek Fine,&nbsp;Jose Manuel Monroy-Trujillo,&nbsp;Antoine Azar,&nbsp;Gabriel Giannini,&nbsp;Homa Timlin","doi":"10.5152/eurjrheum.2022.21059","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn's disease on long-term adalimumab treatment presented with new-onset Raynaud's phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 2","pages":"108-110"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/1c/ejr-9-2-108.PMC10176219.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurjrheum.2022.21059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn's disease on long-term adalimumab treatment presented with new-onset Raynaud's phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿达木单抗致狼疮性肾炎病例报告及文献复习。
肿瘤坏死因子- α抑制剂是已知的系统性红斑狼疮的病原体,但很少涉及狼疮肾炎。克罗恩病患者长期接受阿达木单抗治疗,出现新发雷诺现象,发现有血尿和蛋白尿。发现抗核、抗dsdna和MPO抗体升高。肾活检证实了狼疮性肾炎的诊断。阿达木单抗在尿液检查和dsDNA和MPO抗体检测改善后停用。阿达木单抗可诱发系统性红斑狼疮和狼疮肾炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
56
审稿时长
7 weeks
期刊最新文献
Bullous Cutaneous Lupus Erythematosus and Class V Lupus Nephritis: Rare Concurrence. Comparison and Significance of Contrast-Enhanced Computed Tomographic Findings of Large-Vessel Vasculitis Before and After Treatment: Differences Between Takayasu Arteritis and Giant Cell Arteritis. Evaluation of Rheumatologists' Teledermatology Practices and Perspectives. Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study. Homeopathy for Rheumatological Diseases: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1